Your browser doesn't support javascript.
loading
Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.
Arnold, Michael B; Khanna, Dinesh; Denton, Christopher P; van Laar, Jacob M; Frech, Tracy M; Anderson, Marina E; Baron, Murray; Chung, Lorinda; Fierlbeck, Gerhard; Lakshminarayanan, Santhanam; Allanore, Yannick; Riemekasten, Gabriela; Steen, Virginia; Müller-Ladner, Ulf; Spotswood, Helen; Burke, Laura; Siegel, Jeffrey; Jahreis, Angelika; Furst, Daniel E; Pope, Janet E.
Afiliação
  • Arnold MB; Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
  • Khanna D; Rheumatology, University of Michigan Scleroderma Program, Ann Arbor, MI, USA.
  • Denton CP; Rheumatology and Connective Tissue Diseases, University College London Medical School, London, UK.
  • van Laar JM; Rheumatology & Clinical Immunology, University of Utrecht, Utrecht, The Netherlands.
  • Frech TM; Rheumatology, University of Utah, Veterans Affairs Medical Center, Salt Lake City, UT, USA.
  • Anderson ME; Rheumatology, University of Liverpool and Aintree University Hospital, Liverpool, UK.
  • Baron M; Rheumatology, Jewish General Hospital, Montreal, QC, Canada.
  • Chung L; Medicine and Dermatology, Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, USA.
  • Fierlbeck G; Dermatology, University of Tubingen, Tubingen, Germany.
  • Lakshminarayanan S; Rheumatology, University of Connecticut Health Center, Farmington, CT, USA.
  • Allanore Y; Rheumatology, Paris Descartes University, Paris, France.
  • Riemekasten G; Rheumatology, Charité University Hospital, German Rheumatism Research Center, Berlin, Germany.
  • Steen V; Rheumatology, Georgetown University, Washington, DC, USA.
  • Müller-Ladner U; Lehrstuhl für Innere Medizin mit Schwerpunkt Rheumatologie, Justus-Liebig University Giessen, Kerckhoff Clinic, Bad Nauheim, Germany.
  • Spotswood H; Roche Products Ltd, Welwyn Garden City, UK.
  • Burke L; Roche Products Ltd, Welwyn Garden City, UK.
  • Siegel J; Rheumatology and Rare Diseases, Genentech, South San Francisco.
  • Jahreis A; Rheumatology and Rare Diseases, Genentech, South San Francisco.
  • Furst DE; Rheumatology, University of California, Los Angeles, CA, USA.
  • Pope JE; Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Rheumatology (Oxford) ; 57(1): 152-157, 2018 01 01.
Article em En | MEDLINE | ID: mdl-29077900
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Satisfação do Paciente / Antirreumáticos / Esclerodermia Difusa / Anticorpos Monoclonais Humanizados / Medidas de Resultados Relatados pelo Paciente Tipo de estudo: Clinical_trials / Diagnostic_studies Aspecto: Patient_preference Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Canadá País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Satisfação do Paciente / Antirreumáticos / Esclerodermia Difusa / Anticorpos Monoclonais Humanizados / Medidas de Resultados Relatados pelo Paciente Tipo de estudo: Clinical_trials / Diagnostic_studies Aspecto: Patient_preference Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Canadá País de publicação: Reino Unido